NATIONAL INSTITUTES OF HEALTH
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Extensive Stage Small Cell Lung CancerLimited Stage Small Cell Lung CancerRecurrent Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00470054
- Locations
- πΊπΈ
Cancer and Leukemia Group B, Chicago, Illinois, United States
Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
Phase 1
Completed
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00470197
- Locations
- πΊπΈ
Johns Hopkins University, Baltimore, Maryland, United States
πΊπΈUniversity of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Phase 1
Completed
- Conditions
- Stage IIIC Breast CancerStage IIIB Breast CancerStage IIIA Breast CancerBreast CancerMale Breast CancerStage II Breast Cancer
- Interventions
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00470301
- Locations
- πΊπΈ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
πΊπΈAlbert Einstein College of Medicine, Bronx, New York, United States
πΊπΈMontefiore Medical Center, Bronx, New York, United States
Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer
Phase 2
Completed
- Conditions
- Precancerous ConditionRectal CancerColon Cancer
- Interventions
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 79
- Registration Number
- NCT00468910
- Locations
- πΊπΈ
Northwestern University, Chicago, Illinois, United States
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
Phase 1
Completed
- Conditions
- Adenocarcinoma of the PancreasStage IV Pancreatic CancerUnspecified Adult Solid Tumor, Protocol SpecificRecurrent Pancreatic CancerStage III Pancreatic Cancer
- Interventions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT00462553
- Locations
- πΊπΈ
Case Western Reserve University, Cleveland, Ohio, United States
Lovastatin in Treating Patients At High Risk of Melanoma
Phase 2
Completed
- Conditions
- Stage I MelanomaStage II MelanomaPrecancerous ConditionStage 0 Melanoma
- Interventions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT00462280
- Locations
- πΊπΈ
University of California Medical Center At Irvine-Orange Campus, Orange, California, United States
πΊπΈH. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
πΊπΈHuntsman Cancer Institute, Salt Lake City, Utah, United States
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase 2
Completed
- Conditions
- Recurrent Endometrial Carcinoma
- Interventions
- Biological: ziv-aflibercept
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 49
- Registration Number
- NCT00462826
- Locations
- πΊπΈ
Hartford Hospital, Hartford, Connecticut, United States
πΊπΈThe Hospital of Central Connecticut, New Britain, Connecticut, United States
πΊπΈWashington Hospital Center, Washington, District of Columbia, United States
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- Adult Acute Myeloblastic Leukemia With Maturation (M2)Untreated Adult Acute Myeloid LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Erythroleukemia (M6a)de Novo Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00462605
- Locations
- πΊπΈ
Johns Hopkins University, Baltimore, Maryland, United States
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Phase 2
Completed
- Conditions
- Advanced Malignant MesotheliomaRecurrent Malignant MesotheliomaLocalized Malignant Mesothelioma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT00459862
- Locations
- πΊπΈ
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
Phase 2
Completed
- Conditions
- Recurrent Laryngeal Verrucous CarcinomaRecurrent Lip and Oral Cavity Squamous Cell CarcinomaSalivary Gland Squamous Cell CarcinomaSquamous Cell Carcinoma Metastatic in the Neck With Occult PrimaryStage IV Hypopharyngeal Squamous Cell CarcinomaStage IV Laryngeal Squamous Cell CarcinomaStage IV Laryngeal Verrucous CarcinomaStage IV Lip and Oral Cavity Squamous Cell CarcinomaStage IV Major Salivary Gland CarcinomaRecurrent Laryngeal Squamous Cell Carcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2015-05-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT00458978
- Locations
- πΊπΈ
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States